In the hereditary disease hereditary angioedema (HAE), swellings occur in one or more parts of the body without a recognisable trigger. Especially if the upper respiratory tract is affected, a so-called HAE attack can be life-threatening. Active substances for on-demand medication are so far only available in the form of injections and infusions. In a phase 2 study led by the University Hospital Frankfurt and the Charité – Universitätsmedizin Berlin, it has now been shown for the first time that an orally administered active substance is effective. The therapy could replace the much more time-consuming and stressful injections.
For more information, please see the official press release and the abstract to the paper below.
Press Release Universitätsklinikum Frankfurt
Aygören-Pürsün E, Zanichelli A, Cohn DM, Cancian M, Hakl R, Kinaciyan T, Magerl M, Martinez-Saguer I, Stobiecki M, Farkas H, Kiani-Alikhan S, Grivcheva-Panovska V, Bernstein JA, Li HH, Longhurst HJ, Audhya PK, Smith MD, Yea CM, Maetzel A, Lee DK, Feener EP, Gower R, Lumry WR, Banerji A, Riedl MA, Maurer M. An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial. Lancet. 2023 Feb 11;401(10375):458-469. doi: 10.1016/S0140-6736(22)02406-0. PMID: 36774155.
Read more news from ACARE
- February 23, 2023
In the hereditary disease hereditary angioedema (HAE), swellings occur in one or more parts of the body without a recognisable trigger. Especially if the upper respiratory tract is affected, a [...]
- October 13, 2023
Dr Thomas Buttgereit is joined by Dr Carolina Vera to discuss the use of attenuated androgens in the treatment of hereditary angioedema and their associated risks and side effects. Both [...]
- March 28, 2023
STATE OF THE ART MANAGEMENT OF RECURRENT ANGIOEDEMA AND HANDS ON TRAINING with special focus on Canada and Europe (applied for CME) Click here to register. The overall aim [...]